#chaarted search results

Analysis of APUC-6 gene expression in the #CHAARTED trial cohort. Xiaolei Shi, MD, PhD @UMMC joins @angela_jia_ @RadOncUH discusses biomarker findings from the CHAARTED trial, revealing how six androgen production uptake and conversion genes (APUC-6) combined with AR expression…

Analysis of APUC-6 gene expression in the #CHAARTED trial cohort. Xiaolei Shi, MD, PhD @UMMC joins @angela_jia_ @RadOncUH discusses biomarker findings from the CHAARTED trial, revealing how six androgen production uptake and conversion genes (APUC-6) combined with AR expression…

Utilizing the #CHAARTED and #STAMPEDE2 criteria in the PSMA PET era: Implications on outcomes in metastatic #ProstateCancer. Presentation by @Hoda_Aty @royalmarsdenNHS. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/46Z23ND @myESMO

Analysis of APUC-6 gene expression in the #CHAARTED trial cohort. Xiaolei Shi, MD, PhD @UMMC joins @angela_jia_ @RadOncUH discusses biomarker findings from the CHAARTED trial, revealing how six androgen production uptake and conversion genes (APUC-6) combined with AR expression…

How would you approach this #ProstateCancer case with both #CHAARTED low-volume and #LATITUDE high-risk factors alongside major comorbidities?

Analysis of APUC-6 gene expression in the ECOG-ACRIN #CHAARTED E3805 trial cohort. Xiaolei Shi, MD, PhD @UMMC joins @angela_jia_ @RadOncUH to discuss a potential new biomarker-driven way to guide treatment decisions in #mHSPC. @eaonc #ProstateCancer

Analysis of APUC-6 gene expression in the #CHAARTED trial cohort. Xiaolei Shi, MD, PhD @UMMC joins @angela_jia_ @RadOncUH discusses biomarker findings from the CHAARTED trial, revealing how six androgen production uptake and conversion genes (APUC-6) combined with AR expression…

Validation of six androgen production, uptake, and conversion genes in the ECOG-ACRIN E3805 #CHAARTED #ProstateCancer trial. Presentation by @tranpt21 @UMmedschool. #ASTRO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/46IdYPT @ASTRO_org

Analysis of APUC-6 gene expression in the #CHAARTED trial cohort. Xiaolei Shi, MD, PhD @UMMC joins @angela_jia_ @RadOncUH discusses biomarker findings from the CHAARTED trial, revealing how six androgen production uptake and conversion genes (APUC-6) combined with AR expression…

Prognostic value of PSMA PET against #CHAARTED criteria in an #ENZAMET sub-cohort. Presentation by @Zahra_S_M_. #ASCO25 written coverage > bit.ly/4dQSr9C @RKSayyid @ASCO

Sub-classification of #CHAARTED and #LATITUDE risk categories: Analysis of the discrepancy between high- and low- groups: A multicenter retrospective study. Presentation by Takaki Ichiyama, MD. #AUA25 written coverage by @RKSayyid > bit.ly/42VXZuj @AmerUrological

Impact of PSA nadir on long-term survival in #mHSPC: Final 10-year analysis of the ECOG-ACRIN E3805 #CHAARTED trial. Presentation by @AbhiTrip87 @cityofhope. #GU25 written coverage by @chavarriagaj > bit.ly/4hXTzJc @ASCO

Prognostic power of multi-modal #ArtificialIntelligence biomarker in #CHAARTED trial subset. @MarkowskiGUOnc and @zklaassen_md discuss advancements in AI, particularly the @arteraAI Prostate Test, and its implications for #ProstateCancer treatment > bit.ly/3WrT3tH

Prognostic power of multi-modal #ArtificialIntelligence biomarker in #CHAARTED trial subset. @MarkowskiGUOnc and @zklaassen_md discuss advancements in AI, particularly the @arteraAI Prostate Test, and its implications for #ProstateCancer treatment > bit.ly/3WrT3tH

Prognostic power of multi-modal #ArtificialIntelligence biomarker in #CHAARTED trial subset. @MarkowskiGUOnc and @zklaassen_md discuss advancements in AI, particularly the @arteraAI Prostate Test, and its implications for #ProstateCancer treatment > bit.ly/3WrT3tH

Prognostic power of multi-modal #ArtificialIntelligence biomarker in #CHAARTED trial subset. @MarkowskiGUOnc and @zklaassen_md discuss advancements in AI, particularly the @arteraAI Prostate Test, and its implications for #ProstateCancer treatment > bit.ly/3WrT3tH

Go @AbhiTrip87! Terrific overview of mCSPC, including updates on pivotal studies like @eaonc #CHAARTED (from his presentation at @ASCO 22), #PEACE, #ARASENS, #TITAN & more! @PrimoLaraMD @WalterStadler5 @ShuchiGulati

Validation of six androgen production, uptake, and conversion genes in the ECOG-ACRIN E3805 #CHAARTED #ProstateCancer trial. Presentation by @tranpt21 @UMmedschool. #ASTRO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/46IdYPT @ASTRO_org

@Dr_RaviMadan discussing the quality of life outcomes from #CHAARTED #PROPEL #TALAPRO2 — lots of brainpower on this stage @ASCO #asco23 @OncoAlert

For treatment susceptibility, only pts with LP tumors derived OS benefit from docetaxel (HR 0.21; 95%CI 0.09–0.51) #CHAARTED + only pts with BI tumors derived MFS benefit from adjuvant RT (META855 HR 0.09; 95%CI 0.01–0.71) @Adam_Weiner535 @Davicioni @ChrisSweens1 @EdwardSchaeffer

🌟@anis_a_hamid Ancillary analysis of #CHAARTED, shedding light on germline pathogenic variants in #mHSPC 🌟 1️⃣ The prevalence of #BRCA1/2 and #DDR pathogenic variants, 2️⃣ Highlighting the need for genetic testing at diagnosis. 3️⃣BRCA2 mutations may impact outcomes on ADT…

Research on the prognostic relationship between QOL, disease characteristics, and OS from the #CHAARTED trial on ADT plus docetaxel for mHSPC was presented at #ASCO23. Read more: buff.ly/3IYyGyl

Utilizing the #CHAARTED and #STAMPEDE2 criteria in the PSMA PET era: Implications on outcomes in metastatic #ProstateCancer. Presentation by @Hoda_Aty @royalmarsdenNHS. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/46Z23ND @myESMO

Low- and high-volume disease in metastatic hormone-sensitive #ProstateCancer: From #CHAARTED to PSMA PET. Presentation by @UnterrainerLena @UCLA. #ESMO23 written coverage by @RKSayyid @UofT > bit.ly/46WIGSq @myESMO

Low- and high-volume disease in #mHSPC, from #CHAARTED to PSMA-PET: An international multicenter retrospective study. Presentation by @UnterrainerLena @UCLA. #GU24 written coverage by @zklaassen_md @GACancerCenter > bit.ly/3Ufz9Th @ASCO

Prognostic validation of a digital pathology-based multi-modal #ArtificialIntelligence biomarker in patients with #mHSPC from the #CHAARTED trial. Presented by @MarkowskiGUOnc @HopkinsMedicine. #ASCO24 coverage by @chavarriagaj > bit.ly/4bG1E2D

Landscape and impact of germline pathogenic variants in metastatic hormone-sensitive #ProstateCancer: ancillary study of E3805 #CHAARTED. Presentation by @anis_a_hamid @DanaFarber_GU. #ASCO23 written coverage by @RKSayyid @UofT > bit.ly/3IVPHt1 @ASCO

Patient-reported quality of life and survival outcomes: analysis of ECOG-ACRIN E3805 chemo-hormonal androgen ablation randomized trial #CHAARTED in #ProstateCancer. Presented by Daniel Sentana Lledo, MD @BIDMChealth. #ASCO23 coverage by @RKSayyid @UofT > bit.ly/42hIt9P

Join Daniel Sentana Lledo, MD @BIDMChealth and @CaPsurvivorship @DanaFarber in analyzing quality of life & survival from the #CHAARTED #ProstateCancer trial. Valuable insights for advancing patient care in this discussion on UroToday > bit.ly/3rHxfhY

Impact of PSA nadir on long-term survival in #mHSPC: Final 10-year analysis of the ECOG-ACRIN E3805 #CHAARTED trial. Presentation by @AbhiTrip87 @cityofhope. #GU25 written coverage by @chavarriagaj > bit.ly/4hXTzJc @ASCO

Prognostic power of multi-modal #ArtificialIntelligence biomarker in #CHAARTED trial subset. @MarkowskiGUOnc and @zklaassen_md discuss advancements in AI, particularly the @arteraAI Prostate Test, and its implications for #ProstateCancer treatment > bit.ly/3WrT3tH

Prognostic value of PSMA PET against #CHAARTED criteria in an #ENZAMET sub-cohort. Presentation by @Zahra_S_M_. #ASCO25 written coverage > bit.ly/4dQSr9C @RKSayyid @ASCO

Go @AbhiTrip87! Terrific overview of mCSPC, including updates on pivotal studies like @eaonc #CHAARTED (from his presentation at @ASCO 22), #PEACE, #ARASENS, #TITAN & more! @PrimoLaraMD @WalterStadler5 @ShuchiGulati

Recent studies highlight benefits of hormone therapy in patients with metastatic hormone sensitive #prostatecancer (mHSPC). Our genitourinary medical oncologist, @DrDaveWise, weighs in on key trials #CHAARTED and #STAMPEDE with @OncLive: bit.ly/44OJ6tB

Sub-classification of #CHAARTED and #LATITUDE risk categories: Analysis of the discrepancy between high- and low- groups: A multicenter retrospective study. Presentation by Takaki Ichiyama, MD. #AUA25 written coverage by @RKSayyid > bit.ly/42VXZuj @AmerUrological